Astrazeneca (AZN) Return on Capital Employed (2009 - 2026)
Astrazeneca (AZN) posted quarterly Return on Capital Employed of 16.76% for Q2 2026, up 182.0% year-over-year from 5.94% in Q2 2025, and up 71.63% quarter-over-quarter from 9.76% in Q1 2026.
Astrazeneca (AZN) Return on Capital Employed (2009 - 2026) Analysis & Trends
Astrazeneca's Return on Capital Employed history runs 18 years deep, the most recent figure standing at 16.76% for Q2 2026.
- In Q2 2026, Return on Capital Employed rose 182.0% year-over-year to 16.76%; the TTM figure through Jun 2026 stood at 16.76% (up 182.0% YoY), while the FY2025 annual figure was 17.52%, down 2363.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 16.76%, up from 9.76% in the prior quarter.
- The five-year high for Return on Capital Employed was 78.82% in Q4 2023, with the low at 0.46% in Q2 2022.
- The 5-year median for Return on Capital Employed is 9.22% (2025), against an average of 13.17%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed surged 7111 bps in 2023, then sank 6577 bps in 2024.
- Astrazeneca's Return on Capital Employed stood at 7.71% in 2022, then soared by 922 bps to 78.82% in 2023, then slumped by 83 bps to 13.06% in 2024, then gained by 26 bps to 16.43% in 2025, then advanced by 2 bps to 16.76% in 2026.
- Business Quant data shows AZN's Return on Capital Employed at 16.76% in Q2 2026, 9.76% in Q1 2026, and 16.43% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.76% |
| Mar 31, 2026 | 9.76% |
| Dec 31, 2025 | 16.43% |
| Sep 30, 2025 | 8.68% |
| Jun 30, 2025 | 14.94% |
| Mar 31, 2025 | 7.87% |
| Dec 31, 2024 | 13.06% |
| Sep 30, 2024 | 11.43% |
| Jun 30, 2024 | 11.20% |
| Mar 31, 2024 | 18.06% |
| Dec 31, 2023 | 78.82% |
| Sep 30, 2023 | 7.70% |
| Jun 30, 2023 | 7.25% |
| Mar 31, 2023 | 5.76% |
| Dec 31, 2022 | 7.71% |
| Sep 30, 2022 | 1.97% |
| Jun 30, 2022 | -0.46% |
| Mar 31, 2022 | 0.05% |
| Dec 31, 2021 | 2.12% |
| Sep 30, 2021 | 1.83% |